Abstract
Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Current Pharmaceutical Design
Title: Lactoferricin Derived From Milk Protein Lactoferrin
Volume: 9 Issue: 16
Author(s): H. Wakabayashi, M. Takase and M. Tomita
Affiliation:
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Abstract: Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Export Options
About this article
Cite this article as:
Wakabayashi H., Takase M. and Tomita M., Lactoferricin Derived From Milk Protein Lactoferrin, Current Pharmaceutical Design 2003; 9 (16) . https://dx.doi.org/10.2174/1381612033454829
DOI https://dx.doi.org/10.2174/1381612033454829 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets FLT3 Inhibition in Acute Myeloid Leukaemia – Current Knowledge and Future Prospects
Current Cancer Drug Targets Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Optimizing the Yield of Recombinant Pharmaceutical Proteins in Plants
Current Pharmaceutical Design Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma
Current Drug Targets - Infectious Disorders Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry Liver Stem Cells and Possible Clinical Applications
Current Stem Cell Research & Therapy Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Stem Cells (Guest Editor: Anand Srivastava)]
Current Topics in Medicinal Chemistry Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy MicroRNA Pathways: An Emerging Role in Identification of Therapeutic Strategies
Current Gene Therapy Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Forging New Scaffolds from Old: Combining Scaffold Hopping and Hierarchical Virtual Screening for Identifying Novel Bcl-2 Inhibitors
Current Topics in Medicinal Chemistry Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Gene Expression and Behavior Analysis of PC12 Cells Grown on Synthetic Biodegradable Fibrous Membranes Coated with Natural Biopolymers
Current Nanoscience